## JAZZ: Jazz Pharmaceuticals plc - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 3.5% below STRENGTH zone (4.0-10.0%); PEG 3.97 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-15.9% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($154.29)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 6, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-10 | Piper Sandler | $219 | $147 | +49% |
| 2025-11-24 | UBS | $188 | $163 | +15% |
| 2025-11-18 | Wells Fargo | $235 | $170 | +38% |
| 2025-11-18 | Baird | $209 | $160 | +31% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-10 | Piper Sandler | reit | Overweight |
| 2025-11-24 | UBS | down | Neutral |
| 2025-11-18 | Wells Fargo | main | Overweight |
| 2025-11-18 | Baird | main | Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($0.71M) |
| Sells | 10 ($6.37M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 49.6% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 3 / 6 |

**Top Holders:**
- Vanguard Group Inc: 9.7% (-3.0%)
- Blackrock Inc.: 9.2% (-4.2%)
- JPMORGAN CHASE & CO: 6.2% (+117.0%)
- Dimensional Fund Adv: 4.7% (+11.8%)
- Capital World Invest: 4.2% (+0.4%)

### Key Risks

1. Insider selling cluster: $6.4M in recent transactions.
2. Valuation stretched: PEG 4.0x requires aggressive growth execution.
3. Elevated short interest (9.2%): bears positioning against stock.

### Catalysts

- Analyst target momentum: 6 raises (avg +25%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 3.97 signals overvaluation risk, limited margin of safety. Forward P/E 7.3x attractive for 180% earnings growth. Analyst sentiment positive (6 raises, avg +25%). Insider selling cluster ($6.4M in 90 days), potential headwind. Institutional flow bullish (3 buying vs 6 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $10.0B |
| Beta | 0.31 |
| 52W Range | $95.49 - $182.99 |
| Short Interest | 9.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 3.97 |
| Forward P/E | 7.3 |
| Current P/E | 20.6 |
| YoY Growth | 180.0% |
| EPS Direction | RISING |

### Technicals

MRS_20 deteriorating from 19.4% to 3.5% (-15.9% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 0.5pp (needs >4.0% for momentum thesis). MRS_5 (-5.1%) diverging from MRS_20 - short-term weakness emerging. AM_20 at 5.4% shows strong absolute momentum above own 20MA. Outperforming sector by 3.7pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 60.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 3.47% (CS: 86) | Neutral |
| RSI_14 | 59.5 | Neutral |
| MACD Histogram | 0.35 | Bullish |
| vs SMA20 | 1.054x | Above |
| vs SMA50 | 1.154x | Above |
| vs SMA200 | 1.335x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $166.71
- **Stop Loss:** $154.29 (7.5% risk)
- **Target:** $179.13 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 80
- **Position Value:** $13,336.80
- **Portfolio %:** 13.34%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate improvement trajectory. VIX compression from 20.5 to 16.6 over 5 days signals declining fear, while 47% breadth shows narrow but recovering participation. Fed meeting in 6 days creates near-term uncertainty, but AI sector momentum and improving technical setups support selective positioning.*

### Earnings

**Next:** 2026-02-24 (Est: $6.43)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $5.85 | $8.13 | +39.0% |
| 2025Q2 | $-6.25 | $-8.25 | -32.1% |
| 2025Q1 | $4.66 | $1.68 | -63.9% |
| 2024Q4 | $5.81 | $6.60 | +13.6% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*